-
Daiichi Sankyo & AstraZeneca's datopotamab deruxtecan recommended for approval in EU to treat patients with previously treated metastatic HR positive, HER2 negative breast cancer
03 Feb 2025 10:20 GMT
… of single-agent chemotherapy (eribulin, capecitabine, vinorelbine or gemcitabine) in adult … cancers, including non-small cell lung cancer, triple negative breast cancer and … eight phase 3 trials in lung cancer and five phase 3 trials …
-
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
03 Jun 2024 18:48 GMT
… advanced osimertinib-resistant EGFR-mutated lung cancer,” was presented by Turja Chakrabarti … the FDA in combination with capecitabine for the treatment of adult … with extensive-stage small cell lung cancer.
Further information about Puma Biotechnology …
-
Bevacizumab by F. Hoffmann-La Roche for Small-Cell Lung Cancer: Likelihood of Approval
17 May 2024 03:08 GMT
… Avastin in combination with xeloda or paclitaxel is indicated … squamous non-small cell lung cancer (with carboplatin and … carcinoma, non-small cell lung cancer, metastatic colorectal cancer, … adjuvant non small cell lung cancer (NSCLC), metastatic liver …
-
Barriers to Adherence to Standard of Care in Appalachia: A Qualitative Assessment in Gastrointestinal Cancers
29 Jan 2025 16:06 GMT
… system.25–27 In lung cancer, utilization of a navigator … diagnosis and treatment of lung cancer: a systematic overview of … system for patients with lung cancer. Clin J Oncol Nurs … noncompletion in oral adjuvant capecitabine–based chemotherapy in patients …
-
US FDA approves AstraZeneca & Daiichi Sankyo’s Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
29 Jan 2025 04:34 GMT
… investigator’s choice of chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) in … or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating …
-
Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer
04 Mar 2024 10:29 GMT
… nonsquamous non-small cell lung cancer (NSCLC) who … -agent chemotherapy (eribulin, capecitabine, vinorelbine or gemcitabine) … Small Cell Lung Cancer
Nearly 500,000 lung cancer cases were … References:
1 Cancer.net. Lung Cancer – Non-Small Cell: Statistics …
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
27 Jan 2025 23:07 GMT
… investigator’s choice of chemotherapy (capecitabine, paclitaxel or nab-paclitaxel) in … or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating … Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive …
-
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
27 Jan 2025 14:00 GMT
… of Alpha DaRT alongside capecitabine for patients with locally … in treating liver metastases, lung cancer and rectal cancer - … of Alpha DaRT alongside capecitabine in treating locally advanced … treatment delivered into a lung tumor, ten Alpha DaRT sources …
-
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
13 Feb 2024 13:43 GMT
… for alisertib in small cell lung cancer.
“Treatment options for … of alisertib in small cell lung cancer and, more specifically, … FDA in combination with capecitabine for the treatment of … the treatment of small cell lung cancer and breast cancer.
Further …
-
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
10 Jul 2024 18:05 GMT
… of neoadjuvant treatment with capecitabine plus temozolomide (CAPTEM) … to 2% of all lung cancers.1 They are sporadic … oligometastatic non-small-cell lung cancer without progression after first … for atypical bronchopulmonary carcinoids. Lung Cancer, 90-94, doi: …
About
© 1995-2025